Cargando…

P883: TARGETING CALCINEURIN/NFATC1 SIGNALING SENSITIZES PROTEASOME INHIBITION TREATMENT IN MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales:	Zhang, J., Luo, X., Xia, T., Cheng, K. C., Ng, M. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430536/ http://dx.doi.org/10.1097/01.HS9.0000846408.90988.ee

Ejemplares similares

P01 LACTATE TRAFFICKING INHIBITION RESTORES SENSITIVITY TO PROTEASOME INHIBITHORS AND ORCHESTRATES IMMUNOMICROENVIRONMENT IN MULTIPLE MYELOMA
por: Giallongo, C., et al.
Publicado: (2023)

Inhibition of calcineurin/NFATc4 signaling attenuates ventilator-induced lung injury
por: Li, Min, et al.
Publicado: (2020)

P855: SYNERGISTIC EFFICACY OF COMBINED SUMOYLATION AND PROTEASOME INHIBITION IN MULTIPLE MYELOMA
por: Keller, U., et al.
Publicado: (2022)

Zinc inhibits osteoclast differentiation by suppression of Ca(2+)-Calcineurin-NFATc1 signaling pathway
por: Park, Kwang Hwan, et al.
Publicado: (2013)

Spironolactone Inhibits Cardiomyocyte Hypertrophy by Regulating the Ca(2+)/Calcineurin/p-NFATc3 Pathway
por: Wang, Xin, et al.
Publicado: (2021)

Calcineurin-independent NFATc1 signaling is essential for survival of Burkitt lymphoma cells
por: Murti, Krisna, et al.
Publicado: (2023)

P953: PHASE I STUDY OF TQB3602 CAPSULE, AN ORAL PROTEASOME INHIBITOR, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Tang, W., et al.
Publicado: (2022)

Association of Myocardial Changes and Gene Expression of the NFATC1 and NFATC4—Calcineurin Signaling Pathway in Children with Bicuspid Aortic Valve
por: Kamenshchyk, Andrii, et al.
Publicado: (2023)

883. Evaluation of Post-operative Antibiotic Prophylaxis in Patients Undergoing Urologic Procedures
por: Elmarakbi, Mohamed, et al.
Publicado: (2020)

Calcineurin regulates aldosterone production via dephosphorylation of NFATC4
por: Berber, Mesut, et al.
Publicado: (2023)

P950: COMBINED PROTEASOME AND AUTOPHAGY INHIBITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA – A PHASE I TRIAL OF HYDROXYCHLOROQUINE, CARFILZOMIB AND DEXAMETHASONE
por: Slørdahl, T. S., et al.
Publicado: (2022)

P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD3 T-CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST-IN-HUMAN CLINICAL STUDY
por: Wong, Sandy W., et al.
Publicado: (2023)

Tanshinone IIA Protects Against Cardiac Hypertrophy via Inhibiting Calcineurin/Nfatc3 Pathway
por: Tan, Xueying, et al.
Publicado: (2011)

Calcineurin/Nfatc1 signaling links skin stem cell quiescence to hormonal signaling during pregnancy and lactation
por: Goldstein, Jill, et al.
Publicado: (2014)

Parkia speciosa Hassk. Empty Pod Extract Prevents Cardiomyocyte Hypertrophy by Inhibiting MAPK and Calcineurin-NFATC3 Signaling Pathways
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022)

Major vault protein (MVP) negatively regulates osteoclastogenesis via calcineurin-NFATc1 pathway inhibition
por: Yuan, Lichan, et al.
Publicado: (2021)

NFATc1 affects mouse splenic B cell function by controlling the calcineurin–NFAT signaling network
por: Bhattacharyya, Sankar, et al.
Publicado: (2011)

Betulinic Acid Improves Cardiac-Renal Dysfunction Caused by Hypertrophy through Calcineurin-NFATc3 Signaling
por: Hong, Mi-Hyeon, et al.
Publicado: (2021)

Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506?
por: Sieber, Matthias, et al.
Publicado: (2009)

mTORC1 impedes osteoclast differentiation via calcineurin and NFATc1
por: Huynh, HoangDinh, et al.
Publicado: (2018)

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
por: Heynen, Guus J. J. E., et al.
Publicado: (2022)

Proteasome inhibition and its therapeutic potential in multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2010)

Quantitative Phosphoproteomics of Proteasome Inhibition in Multiple Myeloma Cells
por: Ge, Feng, et al.
Publicado: (2010)

Proteasome inhibition: the dawn of novel therapies in multiple myeloma
por: Engelhardt, Monika, et al.
Publicado: (2022)

P844: CHARACTERIZATION OF MULTIPLE MYELOMA CELL LINES WITH ACQUIRED-RESISTANCE TO PROTEASOME INHIBITORS HIGHLIGHTS A LINK BETWEEN RESISTANCE AND METABOLIC DEREGULATION
por: De Boussac, H., et al.
Publicado: (2022)

Calcineurin-NFATc4 Pathway Is Activated Upon K(+)-stimulation of Adrenal Aldosterone Production
por: Berber, Mesut, et al.
Publicado: (2021)

Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno‐microenvironment in multiple myeloma
por: Barbato, Alessandro, et al.
Publicado: (2023)

Arctigenin Inhibits Osteoclast Differentiation and Function by Suppressing Both Calcineurin-Dependent and Osteoblastic Cell-Dependent NFATc1 Pathways
por: Yamashita, Teruhito, et al.
Publicado: (2014)

The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
por: Paradzik, Tina, et al.
Publicado: (2021)

P803: CRIP1 INDUCES PIS RESISTANCE BY FORMING A COMPLEX WITH USP7/PA200 AND ENHANCING PROTEASOME ACTIVITY AND AUTOPHAGY IN MULTIPLE MYELOMA
por: Yu, Zhen, et al.
Publicado: (2023)

P45 HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY CO-INHIBITING THE B2 AND B1 PROTEASOME SUBUNITS
por: Zhou, X., et al.
Publicado: (2023)

P976: BENDAMUSTINE-POMALIDOMIDE-DEXAMETHASONE (BPD) FOR RELAPSED AND/OR REFRACTOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE
por: Yuping, Z., et al.
Publicado: (2022)

P1716: REGULAR HOSPITAL VISITS IMPROVE THE PROGNOSIS OF MULTIPLE MYELOMA PATIENTS
por: Li, X., et al.
Publicado: (2022)

Persistent contamination of raw milk by Campylobacter jejuni ST-883
por: Jaakkonen, Anniina, et al.
Publicado: (2020)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

Calcineurin/NFAT signalling inhibits myeloid haematopoiesis
por: Fric, Jan, et al.
Publicado: (2012)

P1368: OUTPATIENT AUTOTRANSPLANTS FOR PERSONS WITH MULTIPLE MYELOMA
por: Sánchez-Raga, J. M., et al.
Publicado: (2022)

MiR-30 family prevents uPAR-ITGB3 signaling activation through calcineurin-NFATC pathway to protect podocytes
por: Lang, Yue, et al.
Publicado: (2019)

Calcineurin/NFATc2 and PI3K/AKT signaling maintains β-cell identity and function during metabolic and inflammatory stress
por: Darden, Carly M., et al.
Publicado: (2022)

Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells
por: Auner, Holger W., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4uamgsr5qmn2q7gsidlrq4ps04